RTOG 1016
RTOG 1016 tried to spare HPV-positive throat cancer patients the toxicity of cisplatin by using cetuximab instead, and found that survival was worse: cisplatin stays the standard.
Overview
RTOG 1016 randomised 987 patients with HPV-positive oropharyngeal squamous cell carcinoma to accelerated radiotherapy with cisplatin or with cetuximab. Five-year overall survival was 84.6 percent with cisplatin and 77.9 percent with cetuximab, failing non-inferiority, and locoregional failure was higher with cetuximab; overall toxicity was similar (Gillison and colleagues, Lancet 2019). Together with De-ESCALaTE it closed the door on antibody substitution in this good-prognosis disease.
- 84.6 vs 77.9 out of 100 alive at 5 years with Radiotherapy plus cisplatin compared with Radiotherapy plus cetuximab; 6.7 more per 100.
- Roughly one extra person helped for every 15 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: HPV-positive oropharyngeal cancer: radiotherapy with cetuximab versus radiotherapy with cisplatin. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
987 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival at 5 yearsprimary | Radiotherapy plus cisplatin | 406 | 84.6% | - | - | - |
| Radiotherapy plus cetuximab | 399 | 77.9% |
Similar pages
not linked directly; found by shared links- TrialDe-ESCALaTE HPV
Shares Oropharyngeal cancer (tonsil and base of tongue), HPV-positive oropharyngeal cancer, HPV DNA testing and self-sampling, Chemoradiation (chemoradiotherapy, CRT) and the tag radiation-wave4.
- TrialBonner trial (cetuximab plus radiotherapy)
Shares Oropharyngeal cancer (tonsil and base of tongue), Cetuximab, IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma and the tag radiation-wave4.
- TrialRTOG 91-11
Shares Chemoradiation (chemoradiotherapy, CRT), Cisplatin, IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma and the tag radiation-wave4.
- TrialACT II
Shares Chemoradiation (chemoradiotherapy, CRT), Cisplatin, IMRT / IGRT (modern external beam) and the tag radiation-wave4.
- TrialINT-0116 (Macdonald trial)
Shares Chemoradiation (chemoradiotherapy, CRT), IMRT / IGRT (modern external beam) and the tag radiation-wave4.
- TrialCAO/ARO/AIO-94 (German Rectal Cancer Study)
Shares Chemoradiation (chemoradiotherapy, CRT), IMRT / IGRT (modern external beam) and the tag radiation-wave4.
- TrialPRODIGE 23
Shares Chemoradiation (chemoradiotherapy, CRT), IMRT / IGRT (modern external beam) and the tag radiation-wave4.
- TrialEORTC 26951
Shares Chemoradiation (chemoradiotherapy, CRT), IMRT / IGRT (modern external beam) and the tag radiation-wave4.